{
}
UBS has upgraded Revvity (NYSE:RVTY) from Neutral to Buy, forecasting a 45.01% price increase to an average target of $135.48 per share. Institutional ownership has risen by 3.73% to 136,175K shares, with T. Rowe Price increasing its stake significantly. Despite this, the put/call ratio of 1.49 suggests a bearish sentiment.
Citigroup has reduced its price target for Revvity, Inc. to $135 from $155. Revvity specializes in designing and manufacturing measurement devices and analytical instruments across various sectors, with 61% of net sales from medical diagnosis equipment and 39% from analytical tools. Geographically, 46.7% of sales come from the United States, followed by China at 14.4%, the United Kingdom at 4.1%, and other regions at 34.8%.
Priya Pandey, a biotechnology graduate, excels in creating engaging content across various industries, including healthcare and technology. Coherent Market Insights offers comprehensive market intelligence and consulting services, providing detailed reports on sectors like food and beverages and pharmaceuticals, with insights into market dynamics and competitive strategies. The latest report on the Lateral Flow Assay Market forecasts trends and growth from 2024 to 2031, analyzing consumer behavior and regulatory factors while highlighting key players and emerging opportunities.
The global tuberculosis diagnostics market, valued at approximately $2.05 billion in 2023, is projected to grow to $3.6 billion by 2033, driven by advancements in nucleic acid testing and increasing healthcare investments. Key opportunities lie in smear microscopy, active tuberculosis detection, and hospital diagnostics, with significant growth expected in the Asia-Pacific and North America regions. Major players include Beckton, Dickinson and Company, Qiagen, and F. Hoffmann-La Roche, collectively holding a substantial market share.
The global clinical biomarkers market, valued at $25.02 billion in 2023, is projected to reach $47.25 billion by 2031, growing at a CAGR of 8.54%. This growth is driven by rising cancer cases and advancements in diagnostic technologies, despite challenges like high costs and reimbursement issues. Key players include Roche, Abbott, and Johnson & Johnson, with significant developments in biomarker testing for various diseases.
PerkinElmer Inc
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs upgrades revvity outlook to buy with significant price target increase
T. Rowe Price Investment Management Inc.
Janus Henderson Group plc
T. Rowe Price Capital Appreciation Fund FUND
PerkinElmer Inc
USA
Show more
02:03 02.05.2025
citigroup lowers revvity price target amid diverse product offerings
20:41 28.04.2025
lateral flow assay market analysis trends and growth opportunities 2024 to 2031
United States Dollar
QuidelOrtho Corporation
Hologic Inc
Thermo Fisher Scientific Inc.
QIAGEN NV
Siemens AG
Abcam plc
PerkinElmer Inc
Danaher Corporation
Eiken Chemical Co., Ltd.
Becton, Dickinson and Company
Merck KGaA
Bio-Rad Laboratories Inc
Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Biomerieux SA
FRA
ARG
NZL
CAN
TUR
SAU
ARE
USA
RUS
IND
AUS
ESP
GBR
SGP
BRA
IRN
CHN
DEU
MEX
ITA
JPN
Priya Pandey
Show more
09:06 10.01.2025
growth opportunities in the tuberculosis diagnostics market through 2033
Euro
United States Dollar
Bio-Techne Corporation
Thermo Fisher Scientific Inc.
Qiagen N.V.
Bio-Rad Laboratories, Inc.
PerkinElmer Inc
Becton, Dickinson and Company
BioMerieux SA
Abbott Laboratories
USA
Show more
10:21 06.01.2025
global clinical biomarkers market projected to reach 47 billion by 2031
Eurofins Scientific S.E. A
PerkinElmer Inc
Johnson & Johnson Services Inc.
Bio-Rad Laboratories, Inc.
Qiagen N.V.
Merck KGaA
Thermo Fisher Scientific Inc.
General Electric Co
Siemens Healthineers AG
Agilent Technologies, Inc.
F. Hoffmann-La Roche Ltd.
USA
Show more
08:45 16.12.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People: